Moolec Science (MLEC) Gains from Investment Securities (2023 - 2024)

Moolec Science's (MLEC) quarterly Gains from Investment Securities came in at -$215306.0 in Q4 2024, down 40.14% year-on-year from -$359657.2 in Q1 2024, and down 44.64% quarter-over-quarter from -$148860.0 in Q3 2024.

Moolec Science (MLEC) Gains from Investment Securities (2023 - 2024) Analysis & Trends

Moolec Science has disclosed Gains from Investment Securities across 2 years of filings, most recently posting -$215306.0 for Q4 2024.

  • Gains from Investment Securities for Q4 2024 came in at -$215306.0, down 40.14% year-over-year; the trailing twelve-month figure through Dec 2024 was -$287710.0 (changed N/A YoY), and the FY2025 annual result was -$1.5 million, down 1074.43% from the prior year.
  • Gains from Investment Securities came in at -$215306.0 for Q4 2024 at Moolec Science, down from -$148860.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $213930.0 in Q2 2024 to a low of -$215306.0 in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alterity Therapeutics 723,416.35 Bn 723,416.32 Bn -
2 Belite Bio 57,340.00 Bn 57,340.00 Bn -
3 Quantum Biopharma 19,125.08 Bn 19,125.08 Bn -
4 Legend Biotech 3,262.00 Bn 3,261.71 Bn 242.10 Mn
5 Akari Therapeutics 1,789.67 Bn 1,789.67 Bn -
6 Evaxion A 1,480.39 Bn 1,480.37 Bn -
7 Psyence Biomedical 241.78 Bn 241.78 Bn -
8 Vertex Pharmaceuticals 113.54 Bn 106.29 Bn 2.59 Bn
9 Abivax 94.26 Bn 94.26 Bn -
10 Moolec Science 6.98 Bn 6.98 Bn -

Historic Data

Download Data
DateValue
Dec 31, 2024 -215,306.00
Dec 31, 2024 -215,306.00
Sep 30, 2024 -148,860.00
Sep 30, 2024 -148,860.00
Jun 30, 2024 213,930.00
Jun 30, 2024 213,930.00
Mar 31, 2024 -137,474.00
Mar 31, 2024 -137,474.00
Dec 31, 2023 -153,641.00
Dec 31, 2023 -153,641.00
Sep 30, 2023 -48,279.00
Sep 30, 2023 -48,279.00